JULY 29, 2016  BY FINK DENSFORD   Orthobiologics maker Bioventus postponed its initial public offering which was slated to raise up to $150 million for the company, according to Renaissance Capital. The company plans to float 8.8 million shares at a price range of between $16 and $18, and plans to list on the NASDAQ Global Market […]